CONCERT PHARMACEUTICALS INC's ticker is CNCE and the CUSIP is 206022105. A total of 1 filers reported holding CONCERT PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $7,827,352 | +331.7% | 1,340,300 | +395.3% | 0.03% | +285.7% |
Q3 2022 | $1,813,000 | -84.0% | 270,600 | -69.7% | 0.01% | -87.3% |
Q4 2020 | $11,297,000 | +48.4% | 893,741 | +15.3% | 0.06% | +41.0% |
Q3 2020 | $7,611,000 | +315.4% | 775,000 | +320.9% | 0.04% | +225.0% |
Q2 2020 | $1,832,000 | +117.3% | 184,138 | +222.3% | 0.01% | +200.0% |
Q3 2017 | $843,000 | -79.9% | 57,134 | -86.2% | 0.00% | -86.2% |
Q3 2016 | $4,190,000 | -7.7% | 414,479 | +2.5% | 0.03% | -6.5% |
Q2 2016 | $4,542,000 | -5.1% | 404,479 | +15.4% | 0.03% | -16.2% |
Q1 2016 | $4,786,000 | -42.1% | 350,372 | -36.9% | 0.04% | -35.1% |
Q2 2015 | $8,264,000 | +3.9% | 555,000 | +5.7% | 0.06% | +5.6% |
Q1 2015 | $7,954,000 | +19.4% | 525,200 | +5.0% | 0.05% | +14.9% |
Q4 2014 | $6,660,000 | -1.1% | 500,000 | -6.4% | 0.05% | -7.8% |
Q3 2014 | $6,736,000 | – | 534,200 | – | 0.05% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
L1 Capital Pty Ltd | 1,050,124 | $10,312,000 | 3.31% |
Alambic Investment Management, L.P. | 19,934 | $196,000 | 2.15% |
INGALLS & SNYDER LLC | 1,363,603 | $13,391,000 | 0.92% |
ACUTA CAPITAL PARTNERS, LLC | 300,000 | $2,946,000 | 0.80% |
RA Capital Management | 1,858,474 | $18,250,000 | 0.33% |
Perceptive Advisors | 2,150,641 | $21,119,000 | 0.31% |
SPHERA FUNDS MANAGEMENT LTD. | 310,000 | $3,044,000 | 0.30% |
Eversept Partners, LP | 103,829 | $1,019,601 | 0.23% |
Opaleye Management Inc. | 100,000 | $982,000 | 0.19% |
GSA CAPITAL PARTNERS LLP | 58,095 | $570,000 | 0.10% |